Background: Telemedicine is improving acute stroke care in remote areas. Delay in hospital-to-hospital transfer is a common reason why acute ischemic stroke patients are excluded from interventional therapy. The progressive implementation of these procedures, requiring highly specialized professionals in comprehensive stroke centers, will certainly challenge even more the geographic equity in the access to the best acute stroke treatments. We aimed to assess the benefits of telemedicine in selecting stroke patients for endovascular treatments. Methods: In our Reference Comprehensive Stroke Center (RCSC), we perform urgent intra-arterial procedures in acute stroke patients. Patients may be primarily admitted (PA) or referred from community hospitals with (TMHs; 2 centers) or without telemedicine (nonTMHs; 7 centers). We prospectively studied all consecutive stroke patients undergoing urgent endovascular recanalization procedures in the RCSC. We studied different outcome measures according to the patients’ initial admission: PA patients, TMH patients or nonTMH patients. For all patients, demographic and outcome data including serial National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores at 3 months were recorded. Clinical improvement was defined as a decrease ≥4 points on the NIHSS at 7 days or discharge and favorable outcome as mRS ≤2 at 3 months. Whether an endovascular procedure was indicated was decided according to clinical, radiological and transcranial Doppler (TCD) data, independently of the patient’s initial admission center. Results: During a 2-year period, 119 patients received endovascular treatment: PA patients 74 (63.1%), TMH patients 25 (20.5%), nonTM patients 20 (16.4%). The mean distance to the RCSC was 52 ± 15 km for TMHs and 34.5 ± 12 km for nonTMHs (p = 0.4). There were no differences in baseline characteristics including age (71, 71.6 and 66.5 years; p = 0.25), baseline NIHSS (18.5, 19 and 18; p = 0.57) and previous use of intravenous tissue plasminogen activator (56.5, 56.5 and 57.9%; p = 0.95). The rate of recanalization (modified Thrombolysis in Cerebral Infarction Score ≥2a) was similar in all groups (75, 66.6 and 68.4%; p = 0.682). TMH and PA patients had similar clinical improvement (61 vs. 63.8%; p = 0.51) and good functional outcome (36.8 vs. 35.3%; p = 0.722). Conversely, nonTMH patients presented a lesser degree of clinical improvement (31.3%) and poorer functional outcome (15.8%) than TMH (p = 0.019 and p = 0.046) and PA patients (p = 0.05 and p = 0.013). TMH patients had significantly shorter door-to-groin puncture times (47 vs. 69 min; p = 0.047). Conclusions: Telemedicine assessment to select patients for endovascular procedures improves the efficiency in stroke management and possibly the early and long-term outcome in patients receiving intra-arterial reperfusion treatment.

Keywords:
Telemedicine, Endovascular procedures, Intra-arterial thrombolysis, Acute stroke
2.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
3.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
4.
Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP: Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649–1655.
5.
Heuschmann PU, Berger K, Misselwitz B, Hermanek P, Leffmann C, Adelmann M, Buecker-Nott HJ, Rother J, Neundoerfer B, Kolominsky-Rabas PL, German Stroke Registers Study Group, Competence Net Stroke: Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003;34:1106–1113.
6.
Adeoye O, Hornung R, Khatri P, Kleindorfer D: Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952–1955.
7.
Abilleira S, Dávalos A, Chamorro A, Alvarez-Sabín J, Ribera A, Gallofré M, Catalan Stroke Code and Thrombolysis Study Group: Outcomes of intravenous thrombolysis after dissemination of the stroke code and designation of new referral hospitals in Catalonia: the Catalan Stroke Code and Thrombolysis (Cat-SCT) Monitored Study. Stroke 2011;42:2001–2006.
8.
Kleindorfer D, Xu Y, Moomaw CJ, Khatri P, Adeoye O, Hornung R: US Geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke 2009;40:3580–3584.
9.
Pedragosa A, Alvarez-Sabin J, Molina CA, Sanclemente C, Martín MC, Alonso F, Ribo M: Impact of a telemedicine system on acute stroke care in a community hospital. J Telemed Telecare 2009;15:260–263.
10.
Ribo M, Molina CA, Pedragosa A, Sanclemente C, Santamarina E, Rubiera M, Delgado-Mederos R, Maisterra O, Quintana M, Alvarez-Sabin J: Geographic differences in acute stroke care in Catalunya: impact of a regional interhospital network. Cerebrovasc Dis 2008;26:284–288.
11.
Hess DC, Wang S, Hamilton W, Lee S, Pardue C, Waller JL, Gross H, Nichols F, Hall C, Adams RJ: REACH: clinical feasibility of a rural telestroke network. Stroke 2005;36:2018–2020.
12.
Audebert HJ, Kukla C, Clarmann von Claranau S, Kühn J, Vatankhah B, Schenkel J, Ickenstein GW, Haberl RL, Horn M, TEMPiS Group: Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria. Stroke 2005;36:287–291.
13.
Jiménez C, Tur S, Legarda I, Vives B, Gorospe A, Torres J, Merino P, Campillo C: The application of telemedicine for stroke in the Balearic Islands: the Balearic Telestroke project. Rev Neurol 2012;54:31–40.
14.
Ribo M, Alvarez-Sabín J, Montaner J, Romero F, Delgado P, Rubiera M, Delgado-Mederos R, Molina CA: Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke 2006;37:1000–1004.
15.
Gönner F, Remonda L, Mattle H, Sturzenegger M, Ozdoba C, Lövblad KO, Baumgartner R, Bassetti C, Schroth G: Local intra-arterial thrombolysis in acute ischemic stroke. Stroke 1998;29:1894–1900.
16.
Kan PT, Orion D, Yashar P, Levy EI: Intra-arterial thrombolysis and thrombectomy for acute ischemic stroke: technique and results. J Neurosurg Sci 2011;55:151–160.
17.
Rubiera M, Ribo M, Pagola J, Coscojuela P, Rodriguez-Luna D, Maisterra O, Ibarra B, Piñeiro S, Meler P, Romero FJ, Alvarez-Sabin J, Molina CA: Bridging intravenous-intra-arterial rescue strategy increases recanalization and the likelihood of a good outcome in nonresponder intravenous tissue plasminogen activator-treated patients: a case-control study. Stroke 2011;42:993–997.
18.
Prabhakaran S, Ward E, John S, Lopes DK, Chen M, Temes RE, Mohammad Y, Lee VH, Bleck TP: Transfer delay is a major factor limiting the use of intra-arterial treatment in acute ischemic stroke. Stroke 2011;42:1626–1630.
19.
Demaerschalk BM: Seamless integrated stroke telemedicine systems of care: a potential solution for acute stroke care delivery delays and inefficiencies. Stroke 2011;42:1507–1508.
20.
Gallofré M, Abilleira S, Tresserras R, de la Puente ML: The stroke programme of Catalonia. Med Clin (Barc) 2009;133:589–593.
22.
Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, Demchuk AM, Martin R, Mauldin P, Dillon C, Ryckborst KJ, Janis S, Tomsick TA, Broderick JP, Interventional Management of Stroke III Investigators: Methodology of the Interventional Management of Stroke III Trial. Int J Stroke 2008;3:130–137.
23.
Masjuan J, Alvarez-Sabín J, Arenillas J, Calleja S, Castillo J, Dávalos A, Díez Tejedor E, Freijo M, Gil-Núñez A, Fernández JC, Maestre JF, Martínez-Vila E, Morales A, Purroy F, Ramírez JM, Segura T, Serena J, Tejada J, Tejero C: Stroke health care plan (ICTUS II, 2010). Neurologia 2011;26:383–396.
24.
Pedragosa A, Álvarez-Sabín J, Molina CA, Brugués J, Ribó M: Trombólisis endovenosa en un hospital comarcal mediante el sistema teleictus. Rev Neurol 2011;53:139–145.
25.
Shafqat S, Kvedar JC, Guanci MM, Chang Y, Schwamm LH: Role for telemedicine in acute stroke. Feasibility and reliability of remote administration of the NIH stroke scale. Stroke 1999;30:2141–2145.
26.
Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Score Programme early CT Score. Lancet 2000;355:1670–1674.
27.
Montaner J, Alvarez-Sabín J: NIH stroke scale and its adaptation to Spanish. Neurologia 2006;21:192–202.
28.
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D, Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology, Technology Assessment Committee of the Society of Interventional Radiology: Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109–e137.
29.
Wang S, Gross H, Lee SB, Pardue C, Waller J, Nichols FT 3rd, Adams RJ, Hess DC: Remote evaluation of acute ischemic stroke in rural community hospitals in Georgia. Stroke 2004;35:1763–1768.
30.
Alonso de Leciñana M, Egido JA, Casado I, Ribó M, Dávalos A, Masjuan J, Caniego JL, Martínez Vila E, Díez Tejedor E; por el Comitéad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN, Fuentes Secretaría B, Alvarez-Sabin J, Arenillas J, Calleja S, Castellanos M, Castillo J, Díaz-Otero F, López-Fernández JC, Freijo M, Gállego J, García-Pastor A, Gil-Núñez A, Gilo F, Irimia P, Lago A, Maestre J, Martí-Fábregas J, Martínez-Sánchez P, Molina C, Morales A, Nombela F, Purroy F, Rodríguez-Yañez M, Roquer J, Rubio F, Segura T, Serena J, Simal P, Tejada J, Vivancos J: Guidelines for the treatment of acute ischaemic stroke. Neurologia 2011, E-pub ahead of print.
31.
Pfefferkorn T, Holtmannspötter M, Schmidt C, Bender A, Pfister HW, Straube A, Mayer TE, Brückmann H, Dichgans M, Fesl G: Drip, ship, and retrieve: cooperative recanalization therapy in acute basilar artery occlusion. Stroke 2010;41:722–736.
32.
Switzer JA, Hall CE, Close B, Nichols FT, Gross H, Bruno A, Hess DC: A telestroke network enhances recruitment into acute stroke clinical trials. Stroke 2010;41:566–569.
33.
Schwamm LH, Audebert HJ, Amarenco P, Chumbler NR, Frankel MR, George MG, Gorelick PB, Horton KB, Kaste M, Lackland DT, Levine SR, Meyer BC, Meyers PM, Patterson V, Stranne SK, White CJ, American Heart Association Stroke Council; Council on Epidemiology and Prevention, Interdisciplinary Council on Peripheral Vascular Disease; Council on Cardiovascular Radiology and Intervention: Recommendations for the implementation of telemedicine within stroke systems of care: a policy statement from the American Heart Association. Stroke 2009;40:2635–2660.
34.
Mikulik R, Alexandrov AV, Ribo M, Garami Z, Porche NA, Fulep E, Grotta JC, Wojner-Alexandrov AW, Choi JY: Telemedicine-guided carotid and transcranial ultrasound: a pilot feasibility study. Stroke 2006;37:229–230.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.